| human | Q5 |
| P2798 | Loop ID | 289097 |
| P496 | ORCID iD | 0000-0003-1826-4314 |
| P1153 | Scopus author ID | 6603378203 |
| P1556 | zbMATH author ID | hurt.aeron-c |
| P734 | family name | Hurt | Q21497552 |
| Hurt | Q21497552 | ||
| Hurt | Q21497552 | ||
| P735 | given name | Aeron | Q9141603 |
| Aeron | Q9141603 | ||
| P6104 | maintained by WikiProject | WikiProject Mathematics | Q8487137 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q60345944 | A Divergent Hepatitis D-Like Agent in Birds |
| Q57094261 | A Review of DNA Vaccines Against Influenza |
| Q38209673 | A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade |
| Q47711631 | A comparison of a rapid test for influenza with laboratory-based diagnosis in a paediatric population |
| Q30400439 | A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses |
| Q42260738 | A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013. |
| Q28477927 | A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model |
| Q42261275 | A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. |
| Q91697516 | A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir |
| Q44910887 | A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses |
| Q27312788 | A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity |
| Q89654019 | A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions |
| Q59330048 | A universal monoclonal antibody protects against all influenza A and B viruses by targeting a highly conserved epitope in the viral neuraminidase |
| Q30370508 | Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. |
| Q57213622 | An influenza A(H3) reassortant was epidemic in Australia and New Zealand in 2003 |
| Q58542481 | Animal models used to assess influenza antivirals |
| Q65001431 | Antarctic Penguins as Reservoirs of Diversity for Avian Avulaviruses. |
| Q34580640 | Antibody landscapes after influenza virus infection or vaccination. |
| Q30430458 | Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model |
| Q90020996 | Antiviral Therapy for the Next Influenza Pandemic |
| Q30410899 | Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives |
| Q93077009 | Antivirals targeting the polymerase complex of influenza viruses |
| Q42984661 | Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model |
| Q92652524 | Assessing the susceptibility of highly pathogenic avian influenza H5N1 viruses to oseltamivir using embryonated chicken eggs |
| Q34120005 | Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model |
| Q40448797 | Assessment of the RNASound RNA Sampling Card for the Preservation of Influenza Virus RNA |
| Q112277183 | Australia as a global sink for the genetic diversity of avian influenza A virus |
| Q54474935 | Australian surveillance for avian influenza viruses in wild birds between July 2005 and June 2007. |
| Q41183830 | Avian influenza in Australia: a summary of 5 years of wild bird surveillance. |
| Q92765131 | Avian influenza in the Greater Mekong Subregion, 2003-2018 |
| Q59353237 | Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents |
| Q91641612 | Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018 |
| Q91955949 | Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission |
| Q101411128 | Burden of influenza B virus infection and considerations for clinical management |
| Q59330218 | Characterisation of an influenza B variant selected with the neuraminidase inhibitor zanamivir |
| Q36048315 | Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. |
| Q57789668 | Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility |
| Q92316706 | Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors |
| Q50536569 | Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. |
| Q43176572 | Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. |
| Q93101955 | Circulation and characterization of seasonal influenza viruses in Cambodia, 2012-2015 |
| Q30374900 | Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. |
| Q57077387 | Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza |
| Q30352552 | Continued dominance of pandemic A(H1N1) 2009 influenza in Victoria, Australia in 2010 |
| Q57240568 | Correction: Reducing Uncertainty in Within-Host Parameter Estimates of Influenza Infection by Measuring Both Infectious and Total Viral Load |
| Q60907369 | Cross-lineage protection by human antibodies binding the influenza B hemagglutinin |
| Q30388177 | Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza |
| Q47105450 | Detection of adamantane-sensitive influenza A(H3N2) viruses in Australia, 2017: a cause for hope? |
| Q33569528 | Detection of evolutionarily distinct avian influenza a viruses in antarctica |
| Q30381305 | Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. |
| Q57094144 | Divergent Human-Origin Influenza Viruses Detected in Australian Swine Populations |
| Q91800691 | Diversity of A(H5N1) clade 2.3.2.1c avian influenza viruses with evidence of reassortment in Cambodia, 2014-2016 |
| Q51873239 | Double dose oseltamivir for severe influenza--does it help? |
| Q59329983 | Ecology and Evolution of Avian Influenza Viruses |
| Q39973215 | Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa |
| Q28544035 | Epidemiological and virological characteristics of influenza viruses circulating in Cambodia from 2009 to 2011 |
| Q28541953 | Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses |
| Q112722302 | Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model |
| Q41196853 | Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection |
| Q30362700 | Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. |
| Q37256687 | Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques |
| Q37347301 | Evidence for the Introduction, Reassortment, and Persistence of Diverse Influenza A Viruses in Antarctica |
| Q113251441 | Expression of a Functional Mx1 Protein Is Essential for the Ability of RIG-I Agonist Prophylaxis to Provide Potent and Long-Lasting Protection in a Mouse Model of Influenza A Virus Infection |
| Q33877811 | Fc functional antibodies in humans with severe H7N9 and seasonal influenza |
| Q30401424 | Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals |
| Q30419130 | Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011. |
| Q30361045 | Genetic analysis of two influenza A (H1) swine viruses isolated from humans in Thailand and the Philippines. |
| Q92450927 | Genetic variations on 31 and 450 residues of influenza A nucleoprotein affect viral replication and translation |
| Q35844377 | Global circulation patterns of seasonal influenza viruses vary with antigenic drift |
| Q89468411 | Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018 |
| Q56969102 | Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017 |
| Q42204936 | Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. |
| Q41344703 | Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. |
| Q37710503 | Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. |
| Q38627487 | Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. |
| Q60537535 | High levels of antibiotic resistance gene expression among birds living in a wastewater treatment plant |
| Q96437962 | Host-targeted Nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir |
| Q91692073 | Human CD8+ T cell cross-reactivity across influenza A, B and C viruses |
| Q43177625 | Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs |
| Q45080611 | In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors |
| Q37392896 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| Q30356751 | Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. |
| Q43172823 | Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. |
| Q45365406 | Infection of dogs with equine influenza virus: evidence for transmission from horses during the Australian outbreak |
| Q59355371 | Influenza A(H5N1) viruses with A(H9N2) single gene (matrix or PB1) reassortment isolated from Cambodian live bird markets |
| Q101134449 | Influenza and COVID-19: What does co-existence mean? |
| Q30425223 | Influenza antiviral resistance in the Asia-Pacific region during 2011 |
| Q57240687 | Influenza antivirals and resistance: the next 10 years? |
| Q30398099 | Influenza antivirals currently in late-phase clinical trial |
| Q34194046 | Influenza outbreaks during World Youth Day 2008 mass gathering |
| Q37397023 | Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses |
| Q41991090 | Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia |
| Q35877222 | Influenza virus transmission from horses to dogs, Australia |
| Q39027771 | Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility |
| Q46560879 | Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children |
| Q24645944 | Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1) |
| Q43176855 | Isolation of avian influenza viruses from two different transhemispheric migratory shorebird species in Australia |
| Q83230244 | Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin |
| Q64065766 | Meta-transcriptomics reveals a diverse antibiotic resistance gene pool in avian microbiomes |
| Q28543158 | Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013 |
| Q30411999 | Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses |
| Q30415267 | Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination |
| Q59157490 | Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues |
| Q57296842 | Neuraminidase inhibitor resistance in influenza: a clinical perspective |
| Q34648838 | Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient |
| Q50091476 | New options to treat influenza B. |
| Q28548477 | Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses |
| Q30382944 | Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. |
| Q30390856 | Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. |
| Q44616840 | Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. |
| Q30398923 | Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. |
| Q30385172 | Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. |
| Q30368680 | Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management |
| Q46426972 | P19-24. Evaluation of recombinant influenza-SIV vaccines in macaques. |
| Q41854401 | Peramivir and laninamivir susceptibility of circulating influenza A and B viruses |
| Q41842259 | Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses |
| Q30361246 | Performance of six influenza rapid tests in detecting human influenza in clinical specimens. |
| Q43186856 | Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient |
| Q89844108 | Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy |
| Q38867748 | Proposed Surveillance for Influenza A in Feral Pigs |
| Q30376871 | Quantifying relative within-host replication fitness in influenza virus competition experiments. |
| Q113275096 | RIG-I activation inhibits human respiratory syncytial virus replication in mammalian cells and in mouse and ferret models of infection. |
| Q33952453 | Rapid detection of the H275Y oseltamivir resistance mutation in influenza A/H1N1 2009 by single base pair RT-PCR and high-resolution melting |
| Q43210864 | Reassortants in recent human influenza A and B isolates from South East Asia and Oceania |
| Q30151721 | Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context |
| Q34731272 | Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q38149216 | Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. |
| Q30218410 | Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region |
| Q51859456 | Second isirv antiviral group conference: overview. |
| Q40333849 | Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets. |
| Q96016383 | Sequencing B cell receptors from ferrets (Mustela putorius furo) |
| Q90186764 | Serologic Evidence of Exposure to Highly Pathogenic Avian Influenza H5 Viruses in Migratory Shorebirds, Australia |
| Q30431906 | Seroprevalence of seasonal and pandemic influenza a in Kuala Lumpur, Malaysia in 2008-2010. |
| Q37336804 | Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques |
| Q61811870 | Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem |
| Q42253862 | Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution |
| Q35805179 | Surveillance and analysis of avian influenza viruses, Australia. |
| Q45127229 | Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia |
| Q59349892 | Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile |
| Q33263979 | Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. |
| Q43210983 | Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir |
| Q91893839 | Sustained RNA virome diversity in Antarctic penguins and their ticks |
| Q95627225 | Sustained virome diversity in Antarctic penguins and their ticks: geographical connectedness and no evidence for low pathogen pressure |
| Q42216579 | TaqMan real time RT-PCR assays for detecting ferret innate and adaptive immune responses |
| Q57240685 | The Ongoing Battle Against Influenza: Drug-resistant influenza viruses: why fitness matters |
| Q30415934 | The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors |
| Q35249640 | The contrasting phylodynamics of human influenza B viruses. |
| Q30391063 | The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay |
| Q43176412 | The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. |
| Q38215346 | The epidemiology and spread of drug resistant human influenza viruses |
| Q91800481 | The evolution and genetic diversity of avian influenza A(H9N2) viruses in Cambodia, 2015 - 2016 |
| Q30415937 | The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors |
| Q34771174 | The global circulation of seasonal influenza A (H3N2) viruses |
| Q96127476 | The impact of climate and antigenic evolution on seasonal influenza virus epidemics in Australia |
| Q34358215 | The recent establishment of North American H10 lineage influenza viruses in Australian wild waterfowl and the evolution of Australian avian influenza viruses |
| Q36251576 | The significance of increased influenza notifications during spring and summer of 2010-11 in Australia |
| Q41922704 | The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide |
| Q91917768 | Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza |
| Q36760165 | Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques |
| Q37677192 | Uncomplicated Cystitis in an Adult Male Following Influenza B Virus Infection |
| Q42264969 | Universal anti-neuraminidase antibody inhibiting all influenza A subtypes |
| Q92106254 | Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment |
| Q27000668 | Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness |
| Q96578178 | Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility |
| Q96689382 | Viral burden, inflammatory milieu and CD8+ T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study |
| Q62477529 | Virome heterogeneity and connectivity in waterfowl and shorebird communities |
| Q93025210 | Virome heterogeneity and connectivity in waterfowl and shorebird communities |
| Q58105532 | Virus-virus interactions and host ecology are associated with RNA virome structure in wild birds |
| Q41095623 | Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring |
| Q30379353 | Zanamivir-resistant influenza viruses with a novel neuraminidase mutation |
Search more.